Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

1. Optimal patient care in advanced chronic kidney disease progressing to kidney failure.Nature reviews. Nephrology · 2026
   Review
2. Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial.Heart failure reviews · 2025
   Review
3. The factor XIa antibody osocimab strongly inhibits clotting in extracorporeal circuits with human blood and in baboons.Research and practice in thrombosis and haemostasis · 2025
   Article
4. Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry.European journal of heart failure · 2025
   Observational
5. Potassium management and heart failure: a nephrologist's perspective.Clinical kidney journal · 2025
   Article
6. Discontinuation and reinitiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction.European journal of heart failure · 2025
   Article
7. Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?Heart failure clinics · 2024
   Review
8. High-intensity care for GDMT titration.Heart failure reviews · 2024
   Review
9. Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?Cardiology clinics · 2023
   Review
10. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.Heart failure reviews · 2023
    Review
11. Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia:Clinical kidney journal · 2023
    Article
12. Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast….Clinical kidney journal · 2023
    Article
13. Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.ESC heart failure · 2023
    Article
14. Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial.European journal of heart failure · 2022
    Article

Corrections and comments

• Comment on
  Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.2022

Authors and funding

1 author at 1 institution in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as